275 healthy adults, ages 19-64 years, were randomized to one of five groups to receive two doses of 15 µg unadjuvanted influenza A /H5N8 virus vaccine, or two doses of 7.5 or 15 µg of vaccine adjuvanted with AS03 or MF59.
[Clinical Infectious Diseases]